TER

Terns Pharma

Stock
Stock
Ticker: TERN
TERN

Price

Price

CHART BY

Frequently asked questions

Terns Pharma's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -1.033. EPS indicates the company's profitability on a per-share basis.
Currently, 1 analysts cover Terns Pharma's stock, with a consensus target price of $53.00. Analyst ratings provide insights into the stock's expected performance.
Terns Pharma's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$109.62M. EBITDA measures the company's overall financial performance.
Terns Pharma has a free cash flow of -$82.18M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Terns Pharma employs approximately 59 people. It operates in the Health Care sector, specifically within the Biotechnology industry.

Financials

EPS (TTM) 
-1.033
EBITDA (TTM) 
-$109.62M
Free Cashflow (TTM) 
-$82.18M

Analyst Ratings

The price target is $53.00 and the stock is covered by 1 analysts.

Buy

0

Hold

1

Sell

0

Information

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Employees
59
Industries
Biotechnology
Sector
Health Care

Identifier

Primary Ticker
TERN

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation